NEOHIGH SIGNALFINANCIAL10-K

NEO shows severe financial deterioration with net losses deepening 37% to $108M, operating losses worsening 26% to $116M, and cash reserves plummeting 57% to $160M.

The company is burning through cash at an alarming rate while losses continue to mount, raising serious questions about financial sustainability and the need for additional capital. The dramatic decline in cash position from $367M to $160M, combined with worsening operational performance, suggests potential liquidity concerns despite debt reduction efforts.

Comparing 2026-02-17 vs 2025-02-18View on EDGAR →
FINANCIAL ANALYSIS

NEO's financial position deteriorated significantly across all key metrics, with net losses expanding 37% to $108M and operating losses increasing 26% to $116M, while interest expenses surged 359% to $6.9M. While the company reduced total debt by 37% to $342M and cut current liabilities by 71%, these improvements were overshadowed by a dramatic 57% decline in cash to $160M and reduced capital expenditures of 34%, suggesting potential cash conservation measures. The overall picture signals mounting financial stress with deteriorating profitability, declining liquidity, and possible concerns about the company's ability to fund operations without additional capital.

FINANCIAL STATEMENT CHANGES
Interest Expense
P&L
+358.6%
$1.5M$6.9M

Interest expense surged 358.6% — significant debt increase or rising rates materially impacting earnings.

Current Liabilities
Balance Sheet
-70.7%
$301.2M$88.3M

Current liabilities reduced — improved short-term financial position and working capital health.

Cash & Equivalents
Balance Sheet
-56.5%
$367.0M$159.6M

Cash declined 56.5% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

Net Income
P&L
-37.2%
-$78.7M-$108.0M

Net income declined 37.2% — review whether driven by operations, interest costs, or non-recurring items.

Current Assets
Balance Sheet
-36.9%
$596.0M$376.3M

Current assets declined 36.9% — monitor working capital adequacy and short-term liquidity.

Total Debt
Balance Sheet
-36.8%
$541.1M$341.9M

Debt reduced 36.8% — deleveraging strengthens balance sheet and reduces financial risk.

Capital Expenditure
Cash Flow
-34.2%
$41.1M$27.0M

Capex reduced 34.2% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Total Liabilities
Balance Sheet
-28.9%
$735.7M$523.3M

Liabilities reduced 28.9% — deleveraging improves balance sheet strength and financial flexibility.

Operating Income
P&L
-25.8%
-$92.1M-$115.9M

Operating profitability softening — costs rising faster than revenue, watch for margin recovery plan.

Operating Cash Flow
Cash Flow
-25.5%
$7.0M$5.2M

Operating cash flow softened — monitor whether temporary working capital timing or structural deterioration.

LANGUAGE CHANGES
NEW — 2026-02-17
PRIOR — 2025-02-18
ADDED
These forward-looking statements address various matters, including the Company s strategy, planned future operations and related expectations with respect to timing and performance, future financial position, future revenues, growth potential and expected growth drivers, the timing, performance and anticipated benefits of collaboration, partnership and licensing activities, projected costs and capital expenditures, prospects and plans, and objectives of management.
INDUSTRY AND MARKET DATA This Annual Report on Form 10-K may include data obtained from third-party research and industry publications, surveys and studies.
The Company believes that these third-party research and industry publications, surveys and studies are reliable, but has not independently verified the accuracy or completeness of such information.
This Annual Report on Form 10-K also may include data based on the Company s own internal estimates and research, which have not been verified by any independent source.
Any such third-party data, as well as the Company s internal estimates and research, are subject to uncertainty and risk due to a variety of factors, including those described in Part I, Item 1A, Risk Factors and elsewhere in this Annual Report on Form 10-K, which could cause the Company s results to differ materially from those expressed in this Annual Report on Form 10-K.
+7 more — sign up free →
REMOVED
These forward-looking statements address various matters, including the Company s strategy, future operations, future financial position, future revenues, changing reimbursement levels from government payers and private insurers, projected costs, prospects and plans, and objectives of management.
Trademarks The NeoGenomics , Genoptix , Clarient , Inivata , and Trapelo company names and certain logos have been trademarked with the United States Patent and Trademark Office.
We have trademarked or have applications pending for the brand names NEO COMPREHENSIVE, NEO EXPAND, NEOLINK, NEOLAB, NEOACCESS, NEOTYPE, NEOSITE, CHART, COMPASS, eCOMPASS, FLEXREPORT, HEMEFISH, MULTIOMYX, NEOVUE, NEOHELIX, NEONET, NEOLYTX, NEOACCELERATE, NEOENGAGE, NEOPIXEL, NEONUCLEUS, NEOSEEK, NEOEXPLORE, NEOUNIVERSITY, PATHSITE, QUICKPATH, TAM-SEQ, INVISION, INVISIONSEQ, INVISIONFIRST, INVISIONFIRST-LUNG, INVISIONSCAN, PANTRACER, RADAR, and NEORADAR.
We also have trademarked or have pending trademarks for the marketing slogans SERVING PATIENTS, SAVING LIVES , TAKING CANCER PERSONALLY , and UNIVERSAL FUSION EXPRESSION .
Glossary Throughout this 2024 Form 10-K, we may use certain abbreviations, acronyms and terms which are described below: ACA The Patient Protection and Affordable Care Act ACLA American Clinical Laboratory Association AKS Anti-Kickback Statute CAP College of American Pathologists CDx Companion Diagnostic CGP Comprehensive Genetic Profile CLIA Clinical Laboratory Improvement Amendments of 1988 CMS Centers for Medicare and Medicaid Services CRO Contract research organizations DHS Designated health services FCA The federal False Claims Act FDA U.S.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →